Gadeta B.V., a Utrecht, The Netherlands-based startup focused on the discovery and development of novel cancer immunotherapies based on gamma delta (γδ) T cell receptors, completed a €7m Series A funding.
The round was led by Baxalta Ventures and Medicxi Ventures with participation from founders, management and Utrecht Holdings. In conjunction with the funding, Geeta Vemuri from Baxalta Ventures and Michèle Ollier and Giovanni Mariggi from Medicxi Ventures will join the supervisory board.
The company intends to use the funds to start a Phase I/IIa clinical trial of its lead program in acute myeloid leukemia (AML) in early 2017 and to optimize a closed manufacturing system to allow for the beginning of a second clinical trial in solid tumors later in 2017
Co-founded in 2015 by CSO Dr. Jürgen Kuball, CEO Mark de Boer, Utrecht Holdings and Medicxi Ventures (which provided seed capital), Gadeta has developed a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with an enhanced anti-cancer reactivity and combat and eradicate both hematological and solid tumors.
The platform is based on discoveries of Prof. Kuball regarding the role of γδ T cell receptors in the broad recognition of the metabolic differences in hematological and solid tumor cells, and their potential use for the treatment of advanced malignancies.